Smart syringes are gaining significant popularity around the world. These syringes are equipped with safety mechanisms, preventing their reutilization, and hence controlling unsafe injection practices.
In the recent times, the incidence of infections, owing to unsafe injection practices, has increased substantially. According to the WHO, around 1.7 million people were infected with the hepatitis B virus, almost 0.3 million were infected with hepatitis C virus, and approximately 34,000 individuals were reported to be infected with HIV due to unsafe injections in 2014. These cases, together with rising reports of needlestick injuries, have remarkably boosted the demand for smart syringes worldwide over the years.
Smart syringes are generally utilized in vaccination, drug delivery, and blood specimen collection, among which drug delivery is the most common application area for these syringes. The prime end users of smart syringes are hospitals and health maintenance organizations (HMOs), psychiatrists, and diabetic patients. The demand for these syringes has been the highest from hospitals and HMOs over the last few years.
Auto-disabled (AD) syringes are attracting the highest demand among all the smart syringe products due to their single-use characteristic. These syringes find maximum application in the routine administration of medicines and fluids, owing to which the demand for them is likely to remain high over the next few years.
Some of the leading participants in the global market for smart syringes are Smiths Group Plc, B. Braun Melsungen AG, Baxter International Inc., Terumo Medical Corp., Retractable Technologies Inc, Unilife Corp., Revolutions Medical Corp., Medtronic Plc (Covidien), and Becton, and Dickinson and Co.